Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism

Launched by DANDERYD HOSPITAL · Dec 18, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at how certain biological markers in the blood can help identify hidden cancers in patients who have experienced venous thromboembolism (VTE), which is a serious condition where blood clots form in the veins. VTE can sometimes be one of the first signs of cancer, but current methods for screening for cancer in these patients are not very effective. The researchers believe that measuring indicators of inflammation and blood clotting might provide better insight into whether a person has an underlying cancer. Specifically, they are investigating a type of marker called neutrophil extracellular traps (NETs) that could be linked to both cancer and blood clotting issues.

To participate in this study, individuals need to be at least 18 years old and have a confirmed case of VTE, which can be diagnosed through various imaging tests. Participants will be asked to provide blood samples and give their consent to be part of the study. The trial is currently recruiting participants and aims to not only identify potential hidden cancers but also to gather information that could help predict outcomes for those with VTE and cancer. This could be important for improving diagnosis and treatment for patients dealing with both conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography;
• • \> 18 years or older;
• • Written informed consent
• Exclusion Criteria:
• • \> 2 days after VTE diagnosis;
• • No blood withdrawal at baseline